<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="case-report" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychopharmacol Bull</journal-id><journal-id journal-id-type="iso-abbrev">Psychopharmacol Bull</journal-id><journal-id journal-id-type="pmc-domain-id">3103</journal-id><journal-id journal-id-type="pmc-domain">ppb</journal-id><journal-title-group><journal-title>Psychopharmacology Bulletin</journal-title></journal-title-group><issn pub-type="ppub">0048-5764</issn><issn pub-type="epub">2472-2448</issn><publisher><publisher-name>MedWorks Media Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10913866</article-id><article-id pub-id-type="pmcid-ver">PMC10913866.1</article-id><article-id pub-id-type="pmcaid">10913866</article-id><article-id pub-id-type="pmcaiid">10913866</article-id><article-id pub-id-type="pmid">38449474</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Complicated Case Histories</subject></subj-group></article-categories><title-group><article-title>New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Alhassan</surname><given-names initials="A">Ahmed</given-names></name><aff>Alhassan, MD, (ORCID: 0000-0003-4770-9538), PGY2 Psychiatry resident, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL.</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prahad</surname><given-names initials="SR">Srihari R</given-names></name><aff>Prahad, MS-4, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL.</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burk</surname><given-names initials="BG">Bradley G</given-names></name><aff>Burk, Pharm D, BCPP, Clinical Pharmacist, University of Alabama at Birmingham, AL.</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fargason</surname><given-names initials="RE">Rachel E</given-names></name><aff>Fargason, MD, Patrick H. Linton Professor and Medical Quality Officer, Senior Associate Director of Strategic Planning, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Heersink School of Medicine, AL.</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Birur</surname><given-names initials="B">Badari</given-names></name><aff>Birur, MD, Associate Professor, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Heersink School of Medicine, AL.</aff></contrib></contrib-group><author-notes><corresp id="FN1">To whom correspondence should be addressed: Badari Birur, MD, Associate Professor, Department of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama (UAB), Birmingham, AL. Phone: Office: (205) 975-8544; Fax: 205-975-6757; E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:bbirur@uabmc.edu">bbirur@uabmc.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>4</day><month>3</month><year>2024</year></pub-date><volume>54</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">457183</issue-id><fpage>33</fpage><lpage>39</lpage><pub-history><event event-type="pmc-release"><date><day>04</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-04 00:25:15.437"><day>04</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 1964&#8211;2024 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.</copyright-statement><copyright-year>2024</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PB-54-1-33.pdf"/><abstract><p id="P1">Synthetic cannabinoids (SCs), a class of new psychoactive substances (NPS) commonly known as &#8220;spice,&#8221; has rapidly gained popularity and become the most ubiquitous NPS on the illegitimate drug market. SCs, unlike natural cannabis (NC), are not controlled by international drug conventions, posing a significant risk to public health. These substances are easily accessible, relatively inexpensive, and challenging to detect in routine drug screenings. The existing literature provides strong evidence of an association between NC use and psychosis, but there is significantly less data on SC psychosis. We present a clinical case report of a 51-year-old African American female with no known psychiatric history who was admitted to the inpatient psychiatric unit after reported paranoia and altered mental status for the preceding six days. During hospitalization, she exhibited disorganization, persecutory delusions, extreme agitation, and bizarre behaviors that included the concealment of a set of stolen keys in her vagina, necessitating an ethics consult. After consideration of differentials, the patient was diagnosed with substance-induced psychotic disorder secondary to SC. The patient was stabilized on 3 mg Risperidone at bedtime. After 16-day hospitalization, she reached her baseline and later revealed that she had recently smoked SC for the first time. The primary goal of this case is to highlight the sequelae of SC-associated psychosis. A SC-associated psychosis could drastically vary from NC and is often undetectable on a typical UDS, which may result in a lifelong primary psychotic disorder misdiagnosis.</p></abstract><kwd-group><kwd>new onset psychosis</kwd><kwd>synthetic cannabis</kwd><kwd>spice</kwd><kwd>older patient</kwd><kwd>case report</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>